Acute coronary syndrome (ACS) is a syndrome (set of signs and symptoms) due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies. The most common symptom is chest pain, often radiating to the left shoulder or angle of the jaw, crushing, central and associated with nausea and sweating. Many people with acute coronary syndromes present with symptoms other than chest pain, particularly, women, older patients, and patients with diabetes mellitus.
Increase in geriatric population and rise in the incidence of cardiac disorders are the major factors that drive the market growth. However, stringent government regulations for the approval of drugs are expected to restrain the market growth. Improvement in healthcare facilities in emerging regions such as Asia-Pacific and LAMEA are expected to provide new growth opportunities for the market during the analysis period.

Market Analysis and Insights: Global Acute Coronary Syndrome (ACS) Market
The global Acute Coronary Syndrome (ACS) market size is projected to reach US$ 10110 million by 2027, from US$ 7806.3 million in 2020, at a CAGR of 3.7% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Acute Coronary Syndrome (ACS) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Acute Coronary Syndrome (ACS) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Acute Coronary Syndrome (ACS) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Acute Coronary Syndrome (ACS) market.

Global Acute Coronary Syndrome (ACS) Scope and Market Size
Acute Coronary Syndrome (ACS) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Acute Coronary Syndrome (ACS) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Monotherapy
Combination Therapy

Segment by Application
Hospitals
Ambulatory Surgical Center
Diagnostic Centers

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Dexa Medica
GlaxoSmithKline
Novartis
Pfizer
Sanofi
Serum Institute of India
Biogen
Eli Lilly and Company